The Weekly Litigation News Digest is now live. Subscribe now

IP Verse

Astellas Pharma competitive analysis

Loading summary...

Latest patents of Astellas Pharma opposed by its competitors

Explore Astellas Pharma's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Nov 13, 2025
Patent NumberPublication DateTitleTotal Oppositions
EP3791896
Jan 10, 2024Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of Cancer3
EP3318259
Jan 11, 2023Stable Pharmaceutical Composition For Oral Administration2
EP3725810
Jul 6, 2022Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of Cancer2
EP3725778
Aug 18, 2021Formulations Of Enzalutamide12
EP2345410
Dec 30, 2020Controlled Release Pharmaceutical Composition7
EP3254695
Sep 9, 2020Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of Cancer1
EP2824181
Nov 14, 2018Novel Fgfr3 Fusion Product2
EP2554168
Jan 24, 2018Controlled Release Pharmaceutical Composition4

Latest PTAB cases involving Astellas Pharma

Discover the latest PTAB cases involving Astellas Pharma, highlighting their recent legal challenges and patent disputes.

Last updated on: Nov 13, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Astellas Pharma

IPR2018-00079Oct 16, 2017SAWAI PHARMACEUTICALASTELLAS PHARMAInstitution Denied

Peer Comparison New

IP litigation analysis comparing Astellas Pharma with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Nov 13, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
ASTELLAS PHARMA - 33 - 1
HAMM & WITTKOPP112 - - -
MAIWALD136 - - -
SANDOZ1191619 -